BerGenBio ASA (BGBIO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:BerGenBio ASA (BGBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014121
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BerGenBio ASA (BerGenBio) is a developer of drugs for aggressive and drug resistant cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 finds application in the treatment of drug resistant chronic myeloid leukemia. BerGenBio’s cellselect is a drug discovery and validation technology that identifies and validates novel drug targets and biomarkers. The company’s cellselect imaging allows cell sorting, selection and in-vivo disease imaging. Its cellselect modelling and regulated translational tools are used in treating in-vivo modeling. BerGenBio is headquartered in Bergen, Norway.

BerGenBio ASA (BGBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
BerGenBio ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
BerGenBio Secures US$1.3 Million In Venture Financing 14
Partnerships 15
BerGenBio Enters into Agreement with Merck 15
Licensing Agreements 16
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 16
Equity Offering 18
BerGenBio Raises USD47 Million in IPO 18
BerGenBio Raises USD25 Million in Private Placement of Shares 19
BerGenBio Raises USD12 Million in Private Placement of Shares 20
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 21
BerGenBio ASA – Key Competitors 22
BerGenBio ASA – Key Employees 23
BerGenBio ASA – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 18, 2017: BerGenBio: Results for the Second Quarter and Half year 2017 25
May 23, 2017: BerGenBio: Results for the First Quarter 2017 26
Product News 28
11/29/2016: BerGenBio Reports Promising BGB324 Phase I/II Monotherapy Data in Patients with Lung Cancer at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium 28
06/06/2017: BerGenBio’s selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 29
04/12/2016: Rigel Announces Presentation on preclinical research project MerTK at Upcoming American Association of Cancer Research (AACR) Conference 30
01/09/2017: BerGenBio To Present At 9th Annual Biotech Showcase 2017 31
Clinical Trials 32
May 19, 2017: Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017 32
Dec 08, 2016: New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance 33
Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH 2016 34
Sep 25, 2016: New BGB324 study points to novel mechanism to enhance immunotherapy efficacy 35
Jun 07, 2016: BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 36
Apr 18, 2016: BerGenBio presents new data demonstrating that BGB324 enhances checkpoint inhibitor blockade 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
BerGenBio ASA, Pharmaceuticals & Healthcare, Key Facts 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BerGenBio ASA, Deals By Therapy Area, 2011 to YTD 2017 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
BerGenBio Secures US$1.3 Million In Venture Financing 14
BerGenBio Enters into Agreement with Merck 15
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 16
BerGenBio Raises USD47 Million in IPO 18
BerGenBio Raises USD25 Million in Private Placement of Shares 19
BerGenBio Raises USD12 Million in Private Placement of Shares 20
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 21
BerGenBio ASA, Key Competitors 22
BerGenBio ASA, Key Employees 23

★海外企業調査レポート[BerGenBio ASA (BGBIO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FLSmidth & Co AS (FLS):企業の財務・戦略的SWOT分析
    FLSmidth & Co AS (FLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Deutsche Wohnen AG:企業のM&A・事業提携・投資動向
    Deutsche Wohnen AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Wohnen AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Sunningdale Tech Ltd (BHQ):企業の財務・戦略的SWOT分析
    Summary Sunningdale Tech Ltd (Sunningdale) is a chemical company that manufactures and markets tooling and plastic injection moulding components. The company's plastic solutions include product and mould designs, injection moulding, mould fabrication, complementary finishings, and precision assembly …
  • London Stock Exchange Group Plc:戦略・SWOT・企業財務分析
    London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report Summary London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Mecklenburg Electric Cooperative:発電所・企業SWOT分析
    Mecklenburg Electric Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Abcodia Ltd:企業の製品パイプライン分析2018
    Summary Abcodia Ltd (Abcodia) is a clinical stage company that offers commercial development of novel, scientifically validated tests for the early detection of cancer. The company offers Roca Test, a blood test for early ovarian cancer detection. It validates and discovers biomarkers for early diag …
  • Sberbank of Russia:企業のM&A・事業提携・投資動向
    Sberbank of Russia - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sberbank of Russia Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Bonterra Energy Corp (BNE):石油・ガス:M&Aディール及び事業提携情報
    Summary Bonterra Energy Corp (Bonterra) is an oil and gas company. It acquires and develops producing or undeveloped oil and gas properties. It produces crude oil, natural gas and natural gas liquids. The company principally operates in the provinces of Alberta, British Columbia and Saskatchewan in …
  • Moldex-Metric Inc:企業の戦略的SWOT分析
    Moldex-Metric Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Arup Group Ltd:企業の戦略的SWOT分析
    Arup Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Culture Landmark Investment Ltd:企業の戦略・SWOT・財務分析
    Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Natra S.A.:企業の戦略・SWOT・財務情報
    Natra S.A. - Strategy, SWOT and Corporate Finance Report Summary Natra S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Gexa Energy LP:企業の戦略的SWOT分析
    Gexa Energy LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • SandRidge Energy Inc (SD):企業の財務・戦略的SWOT分析
    SandRidge Energy Inc (SD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Abbott Laboratories:企業の戦略・SWOT・財務情報
    Abbott Laboratories - Strategy, SWOT and Corporate Finance Report Summary Abbott Laboratories - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Toagosei Co., Ltd.:企業の戦略・SWOT・財務分析
    Toagosei Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toagosei Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • AMETEK Inc (AME):電力:M&Aディール及び事業提携情報
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturing company that manufactures electronic instruments and electromechanical devices. The company's products include medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys …
  • GeNeuro SA (GNRO):企業の財務・戦略的SWOT分析
    Summary GeNeuro SA (GeNeuro) is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develops therap …
  • Shin Poong PharmCo Ltd (019170):製薬・医療:M&Aディール及び事業提携情報
    Summary Shin Poong PharmCo Ltd (Shin Poong) is a contract manufacturing company that manufactures and markets pharmaceutical products and active pharmaceutical ingredients. The company provides drugs such as psychoneurotic, anti-cancer, cardiovascular, antihistamine, antirheumatic and benign prostat …
  • Fazoli’s System Management, LLC:企業の戦略・SWOT・財務情報
    Fazoli’s System Management, LLC - Strategy, SWOT and Corporate Finance Report Summary Fazoli’s System Management, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆